Cantor Fitzgerald Reiterates “Overweight” Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $7.00 target price on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 208.37% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the company. Needham & Company LLC restated a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, April 11th. Piper Sandler started coverage on Taysha Gene Therapies in a report on Tuesday, April 9th. They set an “overweight” rating and a $9.00 price target for the company. Chardan Capital raised their price objective on Taysha Gene Therapies from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, March 21st. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $6.88.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA opened at $2.27 on Thursday. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 0.54. Taysha Gene Therapies has a 12-month low of $0.50 and a 12-month high of $3.89. The stock has a 50-day moving average price of $2.56 and a 200 day moving average price of $2.10. The stock has a market capitalization of $424.54 million, a P/E ratio of -3.39 and a beta of 0.29.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share (EPS) for the quarter. The business had revenue of $3.60 million for the quarter, compared to analysts’ expectations of $4.75 million. Equities research analysts forecast that Taysha Gene Therapies will post -0.39 EPS for the current fiscal year.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC lifted its stake in shares of Taysha Gene Therapies by 2,035.0% during the 3rd quarter. FMR LLC now owns 24,527,801 shares of the company’s stock worth $77,508,000 after acquiring an additional 23,378,974 shares during the last quarter. RA Capital Management L.P. purchased a new position in Taysha Gene Therapies during the 3rd quarter worth $58,373,000. RTW Investments LP purchased a new position in Taysha Gene Therapies during the 3rd quarter worth $53,382,000. Vanguard Group Inc. increased its holdings in Taysha Gene Therapies by 16.3% during the 4th quarter. Vanguard Group Inc. now owns 6,195,567 shares of the company’s stock worth $10,966,000 after purchasing an additional 867,703 shares during the period. Finally, Avoro Capital Advisors LLC increased its holdings in Taysha Gene Therapies by 11.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 4,355,555 shares of the company’s stock worth $7,709,000 after purchasing an additional 430,555 shares during the period. 77.70% of the stock is owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.